Bardia A et al. Datopotamab deruxtecan in advanced or metastatic HR+/HER2- and triple-negative breast cancer: Results from the phase I TROPION-PanTumor01 study. J Clin Oncol 2024;[Online ahead of print]. Abstract
Bardia A et al. Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol 2024;42(15):1738-44. Abstract
Ganz PA et al. Patient-reported outcomes in OlympiA: A phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer. J Clin Oncol 2024;42(11):1288-300. Abstract
Giordano A et al. Enfortumab vedotin in the HR+/HER2- and triple-negative breast cancer cohorts of EV-202. ASCO 2024;Abstract 1005.
Krop IE et al. Patritumab deruxtecan (HER2-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: A multicenter, phase I/II trial. J Clin Oncol 2023;41(36):5550-60. Abstract
Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients with HER2-low unresectable and/or metastatic breast cancer: Updated survival results from the randomized, phase 3 DESTINY-Breast04 Study. ESMO 2023;Abstract 376O.
Schmid P et al. Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pats with locally advanced/metastatic BC (LA/mBC). ESMO Breast 2024;Abstract 1810.
Schmid P et al. Datopotamab deruxtecan (Dato-DXd) + Durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC). ESMO 2023;Abstract 379MO.
Schmid P et al. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage Triple-Negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study. San Antonio Breast Cancer Symposium 2023;Abstract LBA01-01.
Schmid P et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022;386(6):556-67. Abstract
Senkus E et al. Olaparib efficacy in patients with germline BRCA-mutated HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. Int J Cancer 2023;153(4):803-14. Abstract
Tolaney SM et al. ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery. ASCO 2023;Abstract TPS619.
Xu B et al. Sacituzumab tirumotecan (Sac-TMT, also known as SKB264/MK-2870) in patients with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. ASCO 2024;Abstract 104.